SeQuent Scientific Ltd
SEQUENTSeQuent Scientific Ltd
SEQUENT
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 728.06 | 5.59 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.93 | 6.39 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
SeQuent Scientific Limited is a holding company that operates in pharmaceutical sector.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 621.08 | 694.65 | 1,292.62 | 1,047.98 | 1,189.33 | 1,369.98 | 1,423.67 | 1,427.30 | 1,395.45 | 1,450.41 | ||||||||||
Raw Materials | 293.07 | 366.89 | 486.44 | 570.52 | 600.59 | 733.68 | 842.41 | 814.87 | 789.20 | 1,319.85 | ||||||||||
| Power & Fuel Cost | 26.51 | 12.77 | 14.66 | 23.06 | 24.73 | 28.75 | 33.86 | 42.45 | 35.46 | |||||||||||
| Employee Cost | 86.67 | 106.22 | 113.83 | 145.95 | 165.06 | 187.22 | 231.37 | 258.39 | 250.57 | |||||||||||
| Selling & Administrative Expenses | 55.11 | 74.68 | 94.72 | 90.93 | 108.27 | 115.85 | 132.65 | 139.02 | 138.35 | |||||||||||
| Operating & Other expenses | 89.67 | 82.59 | 64.28 | 83.92 | 110.27 | 92.86 | 63.12 | 219.02 | 126.88 | |||||||||||
EBITDA | 70.05 | 51.50 | 518.69 | 133.60 | 180.41 | 211.62 | 120.26 | -46.45 | 54.99 | 130.56 | ||||||||||
| Depreciation/Amortization | 45.72 | 40.07 | 41.34 | 41.92 | 50.62 | 50.60 | 51.54 | 55.69 | 61.54 | 63.55 | ||||||||||
| PBIT | 24.33 | 11.43 | 477.35 | 91.68 | 129.79 | 161.02 | 68.72 | -102.14 | -6.55 | 67.01 | ||||||||||
| Interest & Other Items | 38.15 | 28.34 | 33.07 | 32.80 | 35.71 | 24.38 | 15.77 | 35.52 | 48.09 | 53.98 | ||||||||||
| PBT | -13.82 | -16.91 | 444.28 | 58.88 | 94.08 | 136.64 | 52.95 | -137.66 | -54.64 | 13.03 | ||||||||||
| Taxes & Other Items | 4.65 | -3.08 | 22.72 | 10.22 | 24.17 | 41.19 | 11.98 | -16.50 | -18.77 | 7.56 | ||||||||||
| Net Income | -18.47 | -13.83 | 421.56 | 48.66 | 69.91 | 95.45 | 40.97 | -121.16 | -35.87 | 5.47 | ||||||||||
| EPS | -0.34 | -0.53 | 15.98 | 1.91 | 2.82 | 3.84 | 1.65 | -4.87 | -1.44 | 0.22 | ||||||||||
| DPS | 0.00 | 0.00 | 0.18 | 0.20 | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.01 | 0.10 | 0.00 | 0.13 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| SeQuent Scientific Ltd | -111.03 | 5.59 | — |
| Sun Pharmaceutical Industries Ltd | 45.08 | 6.43 | 0.75% |
| Cipla Ltd | 31.71 | 4.88 | 0.80% |
| Torrent Pharmaceuticals Ltd | 70.18 | 16.95 | 0.82% |
Price Comparison
Compare SEQUENT with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding SeQuent Scientific Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 4.0817% | Percentage of the fund’s portfolio invested in the stock 0.71% | Change in the portfolio weight of the stock over the last 3 months 0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 73/119 (-9) |
Quant Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3474% | Percentage of the fund’s portfolio invested in the stock 3.97% | Change in the portfolio weight of the stock over the last 3 months -0.32% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/35 (0) |
UTI Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.3068% | Percentage of the fund’s portfolio invested in the stock 1.12% | Change in the portfolio weight of the stock over the last 3 months 0.31% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 34/43 (+2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateAug 21, 2019
Dividend/Share
₹0.20
Ex DateEx Date
Aug 21, 2019
Cash Dividend
Ex DateEx DateNov 20, 2017
Dividend/Share
₹0.20
Ex DateEx Date
Nov 20, 2017
Cash Dividend
Ex DateEx DateSep 16, 2011
Dividend/Share
₹1.50
Ex DateEx Date
Sep 16, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Dividend/Share
₹2.00
Ex DateEx Date
Sep 23, 2010
Sequent Scientific announced that the Annual General Meeting (AGM) of the company will be held on 17 September 2024.Powered by Capital Market - Live
Sequent Scientific announced its receipt of prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using our API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. The WHO prequalification recognizes Sequent Scientific's commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality. The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale,' said Rajaram Narayanan, MD & CEO of Sequent Scientific.Powered by Capital Market - Live
This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using its API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ. Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle income countries. Rajaram Narayanan, MD & CEO of Sequent Scientific, said, 'The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale.' Sequent Scientific is a global pharmaceutical company specializing in Animal Health. With a strong international presence, the company operates in both API and formulation domains. Their focus lies in addressing unmet market needs for livestock, poultry, and companion animals. The company reported net profit of Rs 6.51 crore in Q1 FY25 as compared with net loss of Rs 34.85 crore in Q1 FY24. Net sales jumped 17.1% YoY to Rs 390.21 crore during the quarter. The counter hit 52-week high at Rs 175 in intraday today.Powered by Capital Market - Live
Net profit of Sequent Scientific reported to Rs 6.51 crore in the quarter ended June 2024 as against net loss of Rs 34.85 crore during the previous quarter ended June 2023. Sales rose 17.11% to Rs 390.21 crore in the quarter ended June 2024 as against Rs 333.21 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales390.21333.21 17 OPM %10.75-2.47 - PBDT28.25-17.93 LP PBT12.00-32.17 LP NP6.51-34.85 LP Powered by Capital Market - Live
Sequent Scientific will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Shipping Corporation of India Ltd leads gainers in ‘A’ group
Sequent Scientific - Worst Of The Disruption, Price Compression Behind: Yes Securities
Sensex tanks 366 points, Nifty settles below 19,450; Hindware Home, Sequent Scientific, Apollo Tyres down up to 13%
Sequent Scienti Consolidated June 2023 Net Sales at Rs 333.21 crore, down 2.38% Y-o-Y
Sequent Scientific slumps 6% after Q1 loss widens to Rs 34.7 cr
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 5.89%, vs industry avg of 9.21%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.46% to 0.37%